X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the collaboration, Aethon will use its HapImmune™ platform to discover novel bispecific antibodies to mount an immune attack directed towards cancer cells hit by Revolution Medicines' RAS(ON) inhibitors.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Large molecule
Recipient: Aethon Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 04, 2024
Details:
Through the acquisition, Revolution expects to conduct late-stage development of RAS(ON) inhibitor drug candidate pipeline, including RMC-6236, in multiple RAS-driven cancers.
Lead Product(s): RMC-6236
Therapeutic Area: Oncology Product Name: RMC-6236
Highest Development Status: Phase IProduct Type: Small molecule
Recipient: EQRx
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition November 09, 2023
Details:
RMC-9805, an oral, covalent, mutant-selective KRASG12D(ON) Inhibitor which is designed to treat patients with cancers driven by the KRASG12D mutation.
Lead Product(s): RMC-9805
Therapeutic Area: Oncology Product Name: RMC-9805
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 19, 2023
Details:
Through the acquisition, Revolution expects to conduct late-stage development of RAS(ON) inhibitor drug candidate pipeline, including RMC-6236, in multiple RAS-driven cancers.
Lead Product(s): RMC-6236
Therapeutic Area: Oncology Product Name: RMC-6236
Highest Development Status: Phase IProduct Type: Small molecule
Recipient: EQRx
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition August 01, 2023
Details:
The net proceeds will be used to fund development of RAS(ON) Inhibitor programs, including clinical development of RMC-6236 and RMC-6291 and advancement of RMC-9805 and RAS Companion Inhibitor programs, including RMC-4630 and RMC-5552 into clinical development.
Lead Product(s): RMC-6236
Therapeutic Area: Oncology Product Name: RMC-6236
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: J.P. Morgan
Deal Size: $345.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering March 07, 2023
Details:
The net proceeds will be used to fund development of RAS(ON) Inhibitor programs, including clinical development of RMC-6236 and RMC-6291 and advancement of RMC-9805 and RAS Companion Inhibitor programs, including RMC-4630 and RMC-5552 into clinical development.
Lead Product(s): RMC-6236
Therapeutic Area: Oncology Product Name: RMC-6236
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: J.P. Morgan
Deal Size: $300.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering March 02, 2023
Details:
The company’s RAS(ON) Inhibitors RMC-629 and RMC-6291 are currently in clinical development. Additional RAS(ON) Inhibitors in the company’s pipeline include RMC-9805, currently in IND-enabling development, RMC-8839, and additional compounds targeting other RAS variants.
Lead Product(s): RMC-5552,Undisclosed
Therapeutic Area: Oncology Product Name: RMC-5552
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 19, 2022
Details:
SHP2 (PTPN11), a cellular enzyme in the protein tyrosine phosphatase family, plays an important role in multiple forms of cancer and in regulating the immune system.
Lead Product(s): Vociprotafib,Sotorasib
Therapeutic Area: Oncology Product Name: RMC-4630
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Sanofi
Deal Size: $550.0 million Upfront Cash: $50.0 million
Deal Type: Termination December 07, 2022
Details:
RMC-6291, an oral, selective, covalent KRASG12C(ON) Inhibitor designed to treat patients with cancers driven by the KRASG12C mutation, which exhibits a potential best-in-class preclinical profile.
Lead Product(s): RMC-6291
Therapeutic Area: Oncology Product Name: RMC-6291
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 22, 2022
Details:
RMC-6236, is the first oral, direct RAS inhibitor to be deployed against a tumor harboring the KRAS G12D variant, designed to treat patients with cancers driven by a variety of RAS mutations.
Lead Product(s): RMC-6236
Therapeutic Area: Oncology Product Name: RMC-6236
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 28, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
